X

Trial Profile

Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 10 Apr 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pegcrisantaspase (Primary) ; Venetoclax (Primary)
Indications Acute myeloid leukaemia
Focus Adverse reactions

Most Recent Events

12 Dec 2023 Results of final analysis presented at the 65th American Society of Hematology Annual Meeting and Exposition
30 Nov 2023 According to a Jazz Pharmaceuticals plc media release, data from this trial will be presented at the at the 65th Annual American Society of Hematology (ASH) Annual Meeting from December 9-12.
23 Aug 2023 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com